Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7\% (95\% confidence interval=7.7-25.7\%). After a median follow-up of 73.5 months, 23 patients (34.8\%) had experienced relapse. Five-year actuarial RFS and OS rates were 64\% and 73\%, respectively. Five-year actuarial RFS was 91.7\% in the ypCR group versus 57.8\% in non-ypCR cases.Long-term local control and survival after this very well-tolerated regimen appear encouraging.
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer / E., Fontana; F., Pucci; R., Camisa; S., Bui; S., Galdy; F., Leonardi; F. V., Negri; E., Anselmi; P. L., Losardo; L., Roncoroni; P., Dell'Abate; P., Crafa; Cascinu, Stefano; A., Ardizzoni. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:Feb;33(2)(2013), pp. 725-730.
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
CASCINU, Stefano;
2013-01-01
Abstract
Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7\% (95\% confidence interval=7.7-25.7\%). After a median follow-up of 73.5 months, 23 patients (34.8\%) had experienced relapse. Five-year actuarial RFS and OS rates were 64\% and 73\%, respectively. Five-year actuarial RFS was 91.7\% in the ypCR group versus 57.8\% in non-ypCR cases.Long-term local control and survival after this very well-tolerated regimen appear encouraging.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
